Minutes
Drug Utilization Review Board Meeting
DATE: September 10, 2025

Meeting Purpose: Quarterly Drug Utilization Board Meeting
Meeting opened at 6:00 p.m. by Rebeka Rice, Pharm.D, R.PH.

The meeting was conducted under Massachusetts Public Meeting Law requirements.

Attendance: Diane Bruessow, DMS, PA-C, CPXP, DFAAPA; Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Timothy Fensky, RPh; Colleen Labelle, MSN, RN-BC, CARN; Jaqueline Gagnon, RPh; Lori Lewicki, RPh; Mathew Moll, MD, MPH; Mirembe Reed, PharmD.; Laura Spring, MD; Karen Ryle, MS, RPh; Rebeka Rice, Pharm.D, R.PH.; Zenhi Stavre, MD; Christy Stine, MD, PhD

Absent: Bavesh Shah, PharmD

Agenda Items:
- Welcome and Introductory Remarks
- Guest Speakers
- Pipeline Update
- Annual Special Populations Update
- Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis
- MHDL Update
- DUR Operational Update
- MassHealth Update
- Open Forum
- Complement Inhibitors Quality Assurance Analysis

Agenda Item	Discussion	Conclusions/Follow-up
Guest Speakers	• Shirley Quach, Novartis, spoke on Fabhalta. • Audrey Ngyen, MD, spoke on the use of Gomekli.	**Follow-up** N/A
Minutes	Motion to approve the minutes for September 2025 was made by Bruessow and was seconded by Gagnon.	**Follow-up** Minutes are approved.

Agenda Item	Discussion	Conclusions/Follow-up
Pipeline Update	**Pipeline Update by Dr. Jordan Franklin** This pipeline update provided a brief overview of clinical and regulatory updates regarding select pharmaceutical pipeline agents in late-stage development.	**Follow-up** Informational/Advisory
Action	Discussion • Etuvetidigene autotemcel (OTL-103) is a gene therapy being studied for Wiskott-Aldrich Syndrome (WAS). Discussed clinical trial data from the TIG-WAS trial and its place in therapy if approved. • Clemidsogene lanparvovec (RGX-121) is a gene therapy being studied for mucopolysaccharidosis (MPS) II (Hunter Syndrome). Discussed clinical trial data from the CAMPSITE trial and its place in therapy if approved.	**Conclusion** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
Annual Special Populations Update	**Annual Special Populations Update by Dr. Bhakti Patel** This was an overview of the current structure of the Drug Utilization Special Populations Program. It summarized clinical outcomes of the program over the past year.	**Follow-up** Informational/Advisory
Action	Discussion • Provided an overview of the MassHealth Special Populations Program • Discussed sample consults • Summarized managed care pharmacy resident involvement • Reviewed financial and clinical outcomes of pharmacist interventions • Outlined the Prior Authorization (PA) Recertification Outreach Program Conclusions • The Special Populations Program encouraged collaboration among MassHealth programs to improve member outcomes. • Outcomes suggested that the MassHealth Special Populations Program has a positive impact on MassHealth members and potential cost savings for MassHealth. • Plan to continue evaluation of the MassHealth Special Populations Program to identify opportunities to improve outreach outcomes and expand services.	**Conclusion** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
	• Potential changes to timeline of provider outreach on expiring prior authorizations (PAs), based on provider feedback; suggest that it may be beneficial to notify providers four to six weeks prior to PA expiration, with a second notification two weeks prior to expiration	

Agenda Item	Discussion	Conclusions/Follow-up
Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis (QA)	**<u>Pediatric Behavioral Health Medication Initiative (PBHMI) Quality Assurance Analysis by Dr. Amy Dionne</u>** This evaluation of current medical literature provided a brief preview of upcoming management changes to the program.	**<u>Follow-up</u>** Informational/Advisory

Action	Discussion
	• Provided an overview of the PBHMI program
	• Reviewed PBHMI workgroup metrics, utilization data, and recent peer-to-peer (PTP) outcomes
	• Discussed recent criteria change based on updated consensus guidelines
	
	Conclusions
	• Annual Utilization Review
	  ○ Prevalence of utilization has remained stable over the last six years and is similar across MH populations.
	  ○ Plan to continue to monitor and present data annually.
	• PBHMI Metrics
	  ○ We review approximately 20% of all PA requiring regimens submitted for review at TCM.
	  ○ Approximately 87% of cases reviewed require a PTP.
	  ▪ Plan to assess high-risk algorithms to ensure review of most appropriate cases.
	• Criteria Changes Implemented in 2024
	  ○ There was an increase in PA submissions and cases reviewed (as expected).
	  ○ There was improved capture of high-risk cases (antipsychotic use in young children).
		<u>Conclusion</u>
		The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up

	• PTP Outcomes Monitoring
	  ○ Demonstrated successful implementation of recommendations; plan to continue the program and refine data collection.
	• Clinical Literature Review
	  ○ Continue to monitor guideline updates annually to ensure that PBHMI program meets clinical standards.	

Agenda Item	Discussion	Conclusions/Follow-up
MassHealth Drug List (MHDL) Update	**MHDL Update by Dr. Chris Nelson** MHDL overview included new additions, changes in PA status, and related attachment updates to be implemented with a recent publication rollout.	**Follow-up** Informational/Advisory

Action	Discussion
	• Effective October 1, 2025:
	  ○ There were 16 additions to the MHDL.
	  ○ There were 11 changes in PA status.
	  ○ There were several changes to Coverage Status; Coverage Status for Brand Name Preferred Over Generic List; Miscellaneous Updates; and 90-day Initiative.
		Conclusion
		The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
MassHealth Update	**MassHealth Update by Dr. Kimberly Lenz** MassHealth update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.	**Follow-up** Informational/Advisory
Action	Discussion • Reviewed current clinical program initiatives • Provided direct negotiation status update • Discussed operational updates	**Conclusion** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up

Agenda Item	Discussion	Conclusions/Follow-up
Open Forum	**Open Forum**	**Follow-up** Informational/Advisory

Agenda Item	Discussion	Conclusions/Follow-up
Complement Inhibitors Quality Assurance (QA)	**Complement Inhibitors Quality Assurance Analysis by Dr. Andrew Coehlo** This was an overview of an evaluation of current medical literature and provided a brief analysis of new guideline recommendations in this disease state.	**Follow-up** Informational/Advisory
Action	Discussion • This presentation was tabled until the next DUR Board meeting.	**Conclusion** N/A.

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: _____